


## **MEDICINAL PRODUCTS 2017**

## **ImmuCell**

# IMMUCELL CORP DE Rank 8 of 44





### **MEDICINAL PRODUCTS 2017**

#### **ImmuCell**

# IMMUCELL CORP DE Rank 8 of 44

The relative strengths and weaknesses of IMMUCELL CORP DE are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of IMMUCELL CORP DE compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 53% points. The greatest weakness of IMMUCELL CORP DE is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 8.4% points.

The company's Economic Capital Ratio, given in the ranking table, is 117%, being 164% points above the market average of -47%.

Input Variable	Value in 1000 USD
Assets, Current	14,348
Assets, Non-Current	34
General and Administrative Expense	3,286
Goodwill	267
Liabilities, Current	2,059
Liabilities, Non-Current	2,916
Other Assets	201
Other Compr. Net Income	26
Other Expenses	4,505
Other Liabilities	0
Other Net Income	0
Other Revenues	9,544
Property, Plant and Equipment, Net	9,846
Research and Development	1,244

Output Variable	Value in 1000 USD
Liabilities	4,975
Assets	24,697
Expenses	9,036
Revenues	9,544
Stockholders Equity	19,722
Net Income	508
Comprehensive Net Income	522
Economic Capital Ratio	117%

